Literature DB >> 24822109

Anti-endothelial cell antibodies in connective tissue diseases associated with pulmonary arterial hypertension.

Xiao-Dan Liu1, Sheng-Yu Guo1, Li-Li Yang1, Xiao-Li Zhang1, Wen-Yi Fu1, Xiao-Fei Wang1.   

Abstract

OBJECTIVE: To investigate the prevalence of anti-endothelial cell antibodies (AECA) in connective tissue diseases (CTD) associated with pulmonary arterial hypertension (PAH) and to corroborate the pathologic function of AECA in PAH-associated CTDs.
METHODS: AECA were detected by cellular enzyme-linked immunosorbent assay (ELISA) in sera of 19 PAH-associated CTD patients, 22 CTD patients without PAH involvement, and 20 age- and sex-matched healthy individuals as controls. Using IgG purified from the sera of AECA-positive, AECA-negative, and healthy subjects, the effects of AECA on the expression of ICAM-1 and the chemokine regulated upon activation normal T-cell expressed and secreted (RANTES) in cultured endothelial cells were also evaluated.
RESULTS: A total of 12 of the 19 (63.2%) CTD patients with PAH, 9 of the 22 (40.9%) CTD patients without PAH, and 1 of the 20 (5%) healthy controls were positive for AECA, which were calculated as ELISA ratio (ER) values. ER values in PAH-associated CTD patients were significantly higher than those with CTD without PAH (3.68±2.05 versus 1.67±1.07, P<0.001). IgG purified from AECA-positive sera induced a significantly increased level of ICAM-1 expression after 48 h incubation (795.2±32.5 pg/mL) compared with AECA-negative or healthy control IgG (231.5±27.1 and 192.8±33.4 pg/mL, respectively; P<0.001). In addition, RANTES production by cultured human pulmonary arterial endothelial cells (HPAECs) increased in both a time- and concentration-dependent manner in response to incubation with purified AECA-positive IgG.
CONCLUSIONS: AECA could be involved in CTD and might participate in the pathogenesis of PAH-associated CTD.

Entities:  

Keywords:  Connective tissue diseases (CTD); anti-endothelial cell antibodies (AECA); pulmonary arterial hypertension (PAH)

Year:  2014        PMID: 24822109      PMCID: PMC4015009          DOI: 10.3978/j.issn.2072-1439.2014.03.27

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  15 in total

1.  Natural anti-endothelial cell antibodies (AECA).

Authors:  N Ronda; S Leonardi; G Orlandini; R Gatti; S Bellosta; F Bernini; A Borghetti
Journal:  J Autoimmun       Date:  1999-08       Impact factor: 7.094

Review 2.  Pathogenic role of anti-endothelial cell antibodies in systemic vasculitis.

Authors:  S Praprotnik; B Rozman; M Blank; Y Shoenfeld
Journal:  Wien Klin Wochenschr       Date:  2000-08-25       Impact factor: 1.704

3.  [Diagnosis and treatment of pulmonary hypertension: European guidelines 2009].

Authors:  M M Hoeper; H A Ghofrani; M Gorenflo; E Grünig; D Schranz; S Rosenkranz
Journal:  Pneumologie       Date:  2010-05-18

Review 4.  Endothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension.

Authors:  Marc Humbert; David Montani; Frédéric Perros; Peter Dorfmüller; Serge Adnot; Saadia Eddahibi
Journal:  Vascul Pharmacol       Date:  2008-06-20       Impact factor: 5.773

5.  IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines.

Authors:  D Carvalho; C O Savage; C M Black; J D Pearson
Journal:  J Clin Invest       Date:  1996-01-01       Impact factor: 14.808

6.  Anti-endothelial cell IgG antibodies from patients with Wegener's granulomatosis bind to human endothelial cells in vitro and induce adhesion molecule expression and cytokine secretion.

Authors:  N Del Papa; L Guidali; M Sironi; Y Shoenfeld; A Mantovani; A Tincani; G Balestrieri; A Radice; R A Sinico; P L Meroni
Journal:  Arthritis Rheum       Date:  1996-05

Review 7.  Inflammation in pulmonary arterial hypertension.

Authors:  P Dorfmüller; F Perros; K Balabanian; M Humbert
Journal:  Eur Respir J       Date:  2003-08       Impact factor: 16.671

Review 8.  The pathology of scleroderma vascular disease.

Authors:  Jo Nadine Fleming; Stephen Mark Schwartz
Journal:  Rheum Dis Clin North Am       Date:  2008-02       Impact factor: 2.670

Review 9.  Anti-endothelial cell antibodies in systemic sclerosis.

Authors:  C Mihai; J W C Tervaert
Journal:  Ann Rheum Dis       Date:  2010-02       Impact factor: 19.103

10.  Anti-endothelial cell antibodies are prevalent in juvenile idiopathic arthritis: implications for clinical disease course and pathogenesis.

Authors:  Bradley J Bloom; Mieko Toyoda; Anna Petrosian; Stanley Jordan
Journal:  Rheumatol Int       Date:  2006-12-13       Impact factor: 3.580

View more
  3 in total

1.  Cytokines, Chemokines, and Inflammation in Pulmonary Arterial Hypertension.

Authors:  Shuxin Liang; Ankit A Desai; Stephen M Black; Haiyang Tang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial.

Authors:  Roham T Zamanian; David Badesch; Lorinda Chung; Robyn T Domsic; Thomas Medsger; Ashley Pinckney; Lynette Keyes-Elstein; Carla D'Aveta; Meagan Spychala; R James White; Paul M Hassoun; Fernando Torres; Andrew J Sweatt; Jerry A Molitor; Dinesh Khanna; Holden Maecker; Beverly Welch; Ellen Goldmuntz; Mark R Nicolls
Journal:  Am J Respir Crit Care Med       Date:  2021-07-15       Impact factor: 30.528

3.  Bioinformatic exploration of the immune related molecular mechanism underlying pulmonary arterial hypertension.

Authors:  Ruina Huang; Xifeng Zheng; Junxian Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.